New drug combo shows promise for tough esophageal cancer
NCT ID NCT02962063
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests adding the immunotherapy drug durvalumab to standard chemoradiation for people with esophageal or gastroesophageal junction cancer. About 64 participants will receive the combination to see if it is safe and effective. The goal is to improve cancer control without increasing side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- durvalumab (a drug that helps the immune system fight cancer)
- What this could lead to
- If successful, this could lead to a more effective treatment for esophageal cancer by combining immunotherapy with standard chemoradiation.
- What could go wrong
- This is an early-phase trial with only 64 participants, so results may not apply broadly. There is a risk of serious side effects from the combination therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Commack
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Nassau
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering Rockville Centre
Rockville Centre, New York, 11570, United States
-
Memorial Sloan Kettering Westchester
Harrison, New York, 10604, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can an immunotherapy combo shrink stomach tumors before surgery?
- Can adding immunotherapy to chemotherapy improve gastric cancer outcomes?
- Can a smart drug home in on Hard-to-Treat cancers?
- Could a smartphone program supervised by AI boost recovery after stomach cancer surgery?